Connect with us

Daily News

Fortis Healthcare Q4 Loss Widens to ₹9.3 Billion, Firm Starts Recovery Process

Fortis Healthcare Ltd (FHL) declared its financial results for the fourth quarter and financial year 2017-18 in the wee hours of Wednesday after deferring it thrice since May. The hospital chain, which is in the process of finding a buyer or investor, posted a net loss of ₹9.32 billion in Q4FY18, as against a loss of ₹680 million in the corresponding quarter last financial year. The losses were primarily on the back of an exceptional loss of ₹8.33 billion. The company said in its statement to the exchanges that the results were impacted by continuing business challenges, impairments, and provisions. The revenues, too, fell by 3 percent year-on-year for the fourth quarter to ₹10.8 billion, while the earnings before interest, tax, depreciation, and amortization (EBITDA) fell 11 percent to ₹750 million. The FY18 consolidated revenues stood at ₹45.61 billion, similar to the previous year, while the losses for the full year stood at ₹10.09 billion. The consolidated EBITDA for the full year increased by 7.4 percent to ₹3.89 billion.

The provisions in Q4FY18 are around ₹5.8 billion, the recoverability of which is doubtful. These include certain inter-corporate deposits (ICDs) of ₹4.45 billion, loans given to body corporates and interest thereon of ₹255 million. Meanwhile, Independent Director Rohit Bhasin, who was appointed to the Fortis board in May, tendered his resignation effective June 26. The board of directors has said that the company has initiated legal action for recovery of these outstanding ICDs and other advances. It made provisions in the un-audited financial results in relation to the ICDs and other matters identified in the Luthra and Luthra investigation report, FHL said. The company would now appoint an external agency to undertake scrutiny of the internal controls and compliance framework and would also evaluate the internal organizational structure and reporting lines, delegation of powers of the board, among other things.

Fortis Healthcare Chairman (board of directors) Ravi Rajagopal said, “As a result of the Investigation Report issued by Luthra & Luthra, the company will appoint an external agency of repute to establish the highest level of governance and internal controls. In addition, our key priority is to ensure that the current bidding process is fair and transparent and maximises value for shareholders.” Fortis has also treated as non-est the letter of appointment (dated September 27, 2016) as amended LoA issued to erstwhile executive chairman Malvinder Singh in relation to his role as lead, strategic initiatives. “The Company is in the process of taking suitable legal measures to recover the payments made to him under the LoA as also to recover all company assets in his possession,” the statement said. In another significant development, Fortis has mentioned that ‘third parties’ related to promoter group have filed a civil suit before the district court, Delhi, in February this year claiming implied ownership of brands Fortis, SRL and La Femme, in addition to financial claims. The company stated that it has not signed the alleged binding term sheet with certain parties. – Business Standard